Nemaura Medical Appoints Thomas Mortensen as Head of E.U. Commercial Operations and Marketing
February 04 2021 - 8:30AM
Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”),
a medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces the appointment of Thomas Mortensen as head of E.U.
commercial operations and marketing.
“Tom is an important addition to our team, as he
will head up our operations in the E.U for our planned direct to
consumer product. His extensive experience throughout Europe will
help us determine the best way to position our products for
country-specific audiences, and we look forward to his leadership
and guidance as we ramp up our marketing activities,” said Faz
Chowdhury, Ph.D., Nemaura’s CEO.
Mr. Mortensen has spent more than 25 years in
commercialization and marketing for the medical device industry,
mostly connected with cardiovascular disease and diabetes. Most
recently he served as head of marketing at Roche Diabetes Care,
where he oversaw the digitalization of its organization, creating a
more efficient and successful working group. In addition, he held
leadership positions at Sunshine Heart, Inc., Mivi Neuroscience, BG
Medicine, Inc., Circulite, Inc., and ev3, Inc. He holds a Bachelor
of Science degree from the Southern Denmark Business School and an
MBA from Odense University, Denmark.
“I look forward to working with the Nemaura team
to bring what I believe is an innovative approach to diabetes care,
with a clear history of clinical evidence to back it up. The
integration of behavioral modification and a wearable, disposable
device to closely monitor glucose trends is a brand new and
non-invasive methodology to truly impact the well-being of people
with diabetes and pre-diabetes,” added Mr. Mortensen.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The Company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and is expected to be launched in the U.S. as a general
wellness product.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit
www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the US, risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate their decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
Contact:Jules AbrahamCORE
IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024